Payment overview · 2025
General Payments
$519.00
29 reported records · 12 companies
Healthcare provider profile · identity verified
Jeff M Sloyer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BURLINGTON, KS · NPI 1215931175
Verified facts
What the public records show
CMS Open Payments records show Jeff M Sloyer, M.D. received $519.00 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.89 | 18.7% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.73 | 12.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.11 | 11.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.34 | 10.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.49 | 9.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.96 | 8.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $44.91 | 8.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.94 | 6.2% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $19.98 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.73 | 3.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.07 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.85 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $519.00 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.89 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.63 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.73 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.11 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $44.91 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 77 |
| Lisinopril | Lisinopril | 385 | 73 |
| Furosemide | Furosemide | 321 | 66 |
| Gabapentin | Gabapentin | 315 | 54 |
| Potassium Chloride | Potassium Chloride | 279 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 57 |
| Losartan Potassium | Losartan Potassium | 193 | 39 |
| Trazodone Hcl | Trazodone Hcl | 191 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 186 | 31 |
| Meloxicam | Meloxicam | 185 | 45 |
| Montelukast Sodium | Montelukast Sodium | 181 | 34 |
| Metformin Hcl | Metformin Hcl | 180 | 42 |
| Alprazolam | Alprazolam | 158 | 33 |
| Pregabalin | Pregabalin | 156 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 27 |
| Simvastatin | Simvastatin | 143 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 42 |
| Bupropion Xl | Bupropion Hcl | 142 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 24 |
| Carvedilol | Carvedilol | 129 | 33 |
| Morphine Sulfate Er | Morphine Sulfate | 129 | 21 |
| Celecoxib | Celecoxib | 126 | 28 |
| Buspirone Hcl | Buspirone Hcl | 122 | 19 |
| Lorazepam | Lorazepam | 115 | 20 |
| Eliquis | Apixaban | 112 | 20 |
| Risperidone | Risperidone | 110 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 27 |
| Donepezil Hcl | Donepezil Hcl | 101 | 16 |
| Tramadol Hcl | Tramadol Hcl | 100 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 33 |
| Omeprazole | Omeprazole | 95 | 23 |
| Famotidine | Famotidine | 94 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 21 |
| Allopurinol | Allopurinol | 89 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 22 |
| Sertraline Hcl | Sertraline Hcl | 82 | 18 |
| Ibuprofen | Ibuprofen | 78 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 17 |
| Ozempic | Semaglutide | 76 | 14 |
| Glipizide | Glipizide | 75 | 15 |
| Temazepam | Temazepam | 75 | 16 |
| Mirtazapine | Mirtazapine | 74 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 19 |
| Azithromycin | Azithromycin | 73 | 58 |
| Divalproex Sodium | Divalproex Sodium | 73 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 15 |
| Finasteride | Finasteride | 72 | 15 |
| Prednisone | Prednisone | 67 | 25 |
| Lamotrigine | Lamotrigine | 66 | 12 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Methylprednisolone | Methylprednisolone | 62 | 53 |
| Alendronate Sodium | Alendronate Sodium | 60 | 15 |
| Mounjaro | Tirzepatide | 59 | 12 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 51 |
| Clonazepam | Clonazepam | 54 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 30 |
| Spironolactone | Spironolactone | 53 | 13 |
| Tramadol Hcl Er | Tramadol Hcl | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 13 |
| Baclofen | Baclofen | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Glyburide | Glyburide | 43 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Nystatin | Nystatin | 41 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Movantik | Naloxegol Oxalate | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 38 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 25 |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Clonidine | Clonidine | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Erythromycin | Erythromycin Base | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Paliperidone Er | Paliperidone | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 12 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Abilify Maintena | Aripiprazole | 21 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Novolog | Insulin Aspart | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $519.00 · 29 records | ABBVIE INC. | ABRYSVO, Auvelity, CAPVAXIVE, COMIRNATY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, Fluad, Flucelvax, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TONMYA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error